Loading
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Latest filing published 14 May 2026 for Atossa Therapeutics, INC.. Read the official filing
Filing timeline
BuySaleJonathan Finn
Insider track record
Disclosed buys
1
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-10.6%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Jonathan Finn: trading record in brief
Jonathan Finn, listed as senior executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Atossa Therapeutics, Inc. and Cibus, Inc. Between 31 May 2023 and 12 May 2026, the trades on record add up to 3 filings.
No open-market sale appears; the market trades are 1 purchase worth €41k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 2 share grants.
Most recently, on 14 May 2026, the filings show a share grant in Atossa Therapeutics, Inc. The clock since the last published purchase (11 April 2024) now reads 920 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Jonathan Finn
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
10,000 shares0Common StockSEC:0001193125-26-224135:0
25,000 shares@ US$1.77100.0% of flowCommon StockSEC:0000950170-24-043690:0
Canonical exit: 9 Jul 2024 (T+90)
1,206 sharesClass A Common StockSEC:0000899243-23-015559:0
3 of 3 declarations
